GLPwatch
[Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
Med Clin (Barc) · 2014
Last updated 2026-05-28GLP-1 receptor agonists are medications used to treat type 2 diabetes by helping control blood sugar levels. Studies show these drugs effectively lower blood sugar, with some trials reporting reductions of around 1.0% to 1.5% in a measure called glycated haemoglobin (HbA1c) over 26 weeks. They are considered in treatment plans when other methods are insufficient, and certain patient characteristics may make them more effective.
AI summary of the abstract below.
| Journal | Med Clin (Barc), 2014 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists are a new group of drugs for the treatment of type 2 diabetes mellitus (DM2). In the present article, we review the available evidence on the efficacy of GLP-1 receptor agonists as glucose-lowering agents, their place in therapeutic algorithms, and the clinical factors associated with a favorable treatment response. Finally, we describe the clinical characteristics of patients who may benefit from these drugs.
Verbatim abstract via PubMed 25437461 ↗